Menu
Search
|

Menu

Close
X

AstraZeneca PLC AZN.ST (Stockholm Stock Exchange)

537.80 SEK
+3.00 (+0.56%)
As of Feb 16
chart
Previous Close 534.80
Open 536.40
Volume 432,616
3m Avg Volume 447,499
Today’s High 538.40
Today’s Low 533.80
52 Week High 622.00
52 Week Low 461.30
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.33 Mean rating from 3 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
--
8.57
Price to Book (MRQ)
vs sector
--
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
--
15.12
LT Debt to Equity (MRQ)
vs sector
--
11.85
Return on Investment (TTM)
vs sector
--
13.54
Return on Equity (TTM)
vs sector
--
14.80

EXECUTIVE LEADERSHIP

Leif Johansson
Independent Non-Executive Chairman of the Board, Since 2012
Salary: --
Bonus: --
Pascal Soriot
Executive Director and Chief Executive Officer, Since 2012
Salary: £1,190,000.00
Bonus: £1,167,000.00
Marc Dunoyer
Executive Director, Chief Financial Officer, Since 2013
Salary: £707,000.00
Bonus: £624,000.00
Fiona Cicconi
Executive Vice-President, Human Resources, Since 2014
Salary: --
Bonus: --
Sean Bohen
Chief Medical Officer, Executive Vice President - Global Medicines Development, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1 Francis Crick Avenue
Cambridge Biomedical Campus
CAMBRIDGE     CB2 0AA

Phone: +4420.73045000

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

SPONSORED STORIES